Cancer Res Treat.  2004 Oct;36(5):303-307.

Expression of Caspase-3 and c-myc in Non-Small Cell Lung Cancer

Affiliations
  • 1Department of Pathology, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea. sjkang@vincent.cuk.ac.kr
  • 2Department of Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea.
  • 3Department of Diagnostic Radiology, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea.
  • 4Department of Radiation Oncology, t. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea.
  • 5Department of Thoracic Surgery, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea.

Abstract

PURPOSE
Caspase-3 is a cysteine protease that plays an important role in the process of apoptotic cell death, but little has been studied clinically on caspase-3 in lung cancer. Increased c-myc expression can result in mitosis or apoptosis, and its contribution to the pathogenesis and prognosis of lung cancer has gained interest. In the present study, the expressions of caspase-3 and c-myc, along with their possible correlations with prognostic variables, were analyzed in resected non-small cell lung carcinomas (NSCLC). MATERIALS AND METHODS: Archival tumor tissues from 147 previously untreated NSCLC patients were examined by immunohistochemistry for the expressions of caspase-3 and c-myc proteins. Clinical information was obtained through the computerized retrospective database from the tumor registry. RESULTS: The expressions of caspase-3 and c-myc were detected in 60 (88/147) and 16% (24/147) of tumors, respectively. No association was found between caspase-3 and c-myc expressions. A multivariate analysis demonstrated the N status and pathologic stage to be significantly correlated with poor survival (p-value=.018 and .002, respectively), but positive expression of caspase-3 was associated with a good prognosis (p=.03). CONCLUSION: Our data suggest the involvement of caspase-3 in the tumorigenesis of NSCLC. It is also noteworthy that caspase-3 expression might be a favorable prognostic indicator in these tumors.

Keyword

Caspase-3; c-myc; Lung cancer

MeSH Terms

Apoptosis
Carcinogenesis
Carcinoma, Non-Small-Cell Lung*
Caspase 3*
Cell Death
Cysteine Proteases
Humans
Immunohistochemistry
Lung
Lung Neoplasms
Mitosis
Multivariate Analysis
Prognosis
Proto-Oncogene Proteins c-myc
Retrospective Studies
Caspase 3
Cysteine Proteases
Proto-Oncogene Proteins c-myc

Figure

  • Fig. 1 Immunohistochemical staining of caspase-3 (A) and c-myc (B) in primary resected NSCLC. The majority of tumor cells show immunoreactivity in their cytoplasm with some nuclear staining (A), and intense nuclear immunostaining (B) (magnification × 100).

  • Fig. 2 Survival of patients with NSCLC according to the expressions of caspase-3 and c-myc (Kaplan-Meier method).


Reference

1. Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer. 1994; 73:2013–2026. PMID: 8156506.
Article
2. Krajewska M, Wang HG, Krajewski S, Zapata JM, Shabaik A, Gascoyne R, Reed JC. Immunohistochemical analysis of in vivo patterns of expression of CPP32 (Caspase-3), a cell death protease. Cancer Res. 1997; 57:1605–1613. PMID: 9108467.
3. Estrov Z, Thall PF, Talpaz M, Estey EH, Kantarjian HM, Andreeff M, Harris D, Van Q, Walterscheid M, Kornblau SM. Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood. 1998; 92:3090–3097. PMID: 9787143.
Article
4. Donoghue S, Baden HS, Lauder I, Sobolewski S, Pringle JH. Immunohistochemical localization of caspase-3 correlates with clinical outcome in B-cell diffuse large-cell lymphoma. Cancer Res. 1999; 59:5386–5391. PMID: 10537324.
5. Nakagawara A, Nakamura Y, Ikeda H, Hiwasa T, Kuida K, Su MS, Zhao H, Cnaan A, Sakiyama S. High levels of expression and nuclear localization of interleukin-1beta converting enzyme (ICE) and CPP32 in favorable human neuroblastomas. Cancer Res. 1997; 57:4578–4584. PMID: 9377572.
6. Kondo S, Tanaka Y, Kondo Y, Ishizaka Y, Hitomi M, Haqqi T, Liu J, Barnett GH, Alnemri ES, Barna BP. Retroviral transfer of CPP32beta gene into malignant gliomas in vitro and in vivo. Cancer Res. 1998; 58:962–967. PMID: 9500457.
7. Wyllie AH. Apoptosis (The 1992 Frank Rose Memorial Lecture). Br J Cancer. 1993; 67:205–208. PMID: 8431353.
Article
8. Barr LF, Campbell SE, Diette GB, Gabrielson EW, Kim S, Shim H, Dang CV. c-Myc suppresses the tumorigenicity of lung cancer cells and down-regulates vascular endothelial growth factor expression. Cancer Res. 2000; 60:143–149. PMID: 10646866.
9. Prins J, De Vries EG, Mulder NH. The myc family of oncogenes and their presence and importance in small-cell lung carcinoma and other tumour types. Anticancer Res. 1993; 13:1373–1385. PMID: 8239508.
10. Gosney JR, Field JK, Gosney MA, Lye MD, Spandidos DA, Butt SA. c-myc oncoprotein in bronchial carcinoma: expression in all major morphological types. Anticancer Res. 1990; 10:623–628. PMID: 2164348.
11. Yoo J, Kang SJ, Ahn WS, Kim BK. E-Cadherin expression and p53 alterations in soft tissue sarcomas: a possible role in epithelial differentiation. Cancer Res Treat. 2001; 33:343–349.
Article
12. Depraetere V, Golstein P. Dismantling in cell death: molecular mechanisms and relationship to caspase activation. Scand J Immunol. 1998; 47:523–531. PMID: 9652819.
Article
13. Hsia JY, Chen CY, Chen JT, Hsu CP, Shai SE, Yang SS, Chuang CY, Wang PY, Miaw J. Prognostic significance of caspase-3 expression in primary resected esophageal squamous cell carcinoma. Eur J Surg Oncol. 2003; 29:44–48. PMID: 12559076.
Article
14. Jonges LE, Nagelkerke JF, Ensink NG, van der Velde EA, Tollenaar RA, Fleuren GJ, van de Velde CJ, Morreau H, Kuppen PJ. Caspase-3 activity as a prognostic factor in colorectal carcinoma. Lab Invest. 2001; 81:681–688. PMID: 11351040.
Article
15. Persad R, Liu C, Wu TT, Houlihan PS, Hamilton SR, Diehl AM, Rashid A. Overexpression of caspase-3 in hepatocellular carcinomas. Mod Pathol. 2004; 17:861–867. PMID: 15098015.
Article
16. Koomagi R, Volm M. Relationship between the expression of caspase-3 and the clinical outcome of patients with non-small cell lung cancer. Anticancer Res. 2000; 20:493–496. PMID: 10769711.
17. Volm M, Koomagi R. Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival. Br J Cancer. 2000; 82:1747–1754. PMID: 10817513.
18. Takata T, Tanaka F, Yamada T, Yanagihara K, Otake Y, Kawano Y, Nakagawa T, Miyahara R, Oyanagi H, Inui K, Wada H. Clinical significance of caspase-3 expression in pathologic-stage I, non small-cell lung cancer. Int J Cancer. 2001; 96(suppl):54–60. PMID: 11992386.
19. Kubokura H, Tenjin T, Akiyama H, Koizumi K, Nishimura H, Yamamoto M, Tanaka S. Relations of the c-myc gene and chromosome 8 in non-small cell lung cancer: analysis by fluorescence in situ hybridization. Ann Thorac Cardiovasc Surg. 2001; 7:197–203. PMID: 11578259.
20. Volm M, Koomagi R, Mattern J, Efferth T. Protein expression profile of primary human squamous cell lung carcinomas indicative of the incidence of metastases. Clin Exp Metastasis. 2002; 19:385–390. PMID: 12198766.
21. Yakut T, Egeli U, Gebitekin C. Investigation of c-myc and p53 gene alterations in the tumor and surgical borderline tissues of NSCLC and effects on clinicopathologic behavior: by the FISH technique. Lung. 2003; 181:245–258. PMID: 14705768.
Article
Full Text Links
  • CRT
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr